BUZZ – Lipocine shares soar after Canada approves its testosterone replacement therapy
路透社2026/10/07 12:56October 7 - ** Pharmaceutical company Lipocine (LPCN.O) saw its stock price rise 28% in pre-market trading to $2.7. ** Lipocine announced that (link) it has received approval from Health Canada for its oral testosterone replacement therapy drug, Tlando, for the treatment of male hypogonadism. ** In January 2024, Lipocine licensed the commercialization rights for Tlando in the US and Canada to the private company Verity Pharma. ** Lipocine is eligible to receive milestone payments of up to $259 million, as well as royalties ranging from 12% to 18% based on Tlando’s net sales. ** According to Lipocine, over 700,000 prescriptions for testosterone replacement therapy (TRT) are issued annually in Canada, with approximately 50% of patients reimbursed through private insurance. ** TRT is available in multiple formulations, including injections, oral medications, and topical gels. ** As of the previous trading session’s close, LPCN shares had declined by 73% year-to-date. (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Since automatic translations may be inaccurate or lack desired context, Reuters does not guarantee the accuracy of translated content and provides such translations for user convenience only. Reuters accepts no responsibility for any harm or loss resulting from the use of automated translation features.)
October 7 - ** The pharmaceutical company Lipocine (LPCN.O) saw its share price rise 28% to $2.70 in pre-market trading
** LPCN stated (link) that it has received approval from Health Canada for its oral testosterone replacement therapy drug Tlando for the treatment of male hypogonadism
** In January 2024, Lipocine granted commercial rights to Tlando in the United States and Canada to the private company Verity Pharma
** Lipocine is eligible for milestone payments of up to $259 million, as well as royalties of 12% to 18% based on net sales of Tlando
** According to Lipocine, more than 700,000 testosterone replacement therapy (TRT) prescriptions are issued annually in Canada, with about 50% of patients reimbursed by private insurance
** TRT treatment is available in various forms, including injections, oral tablets, and topical creams
** As of the previous trading day's close, LPCN stock had fallen 73% year-to-date
(To assist non-English speakers, Reuters has automated its reports into several other languages. Because automated translation may be inaccurate or lack necessary context, Reuters does not guarantee the accuracy of the automated text and provides it for readers’ convenience only. Reuters assumes no liability for any damage or loss caused by use of the automated translation service.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Barclays significantly increased holdings in Tesla (TSLA.US) and Intel (INTC.US) in Q3, and bought Nasdaq ETF options for hedging
According to disclosures by the U.S. Securities and Exchange Commission (SEC), Barclays has submitted its third-quarter holdings report (13F) as of September 30, 2026.
SNT Holdings, Related Party Raise Combined Stake in SNTEnergy to 55.75% From 52.75%
Cold wave and rising fuel costs drive electricity prices in northeastern Japan and Tokyo to a four-year high
Japan's spot electricity prices surged to multi-year highs over the weekend.
Google (GOOGL.US) warns that new Australian cybersecurity regulations may cut off minors' access to Gmail
Google stated that a new cybersecurity bill in Australia could prevent minors from using Gmail.
Crypto prices
More
